single FMT
Phase 2Biologic
single FMT is one of 46 biologic programs targeting Ulcerative Colitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Stelara
Johnson & JohnsonPhase 3
Jyseleca
GileadPhase 3
Skyrizi
AbbViePhase 3
Humira
RRanbaxy Laboratories Limited
Phase 3
Velsipity
PfizerPhase 3
Mesalazine
FerringPhase 3
Plaquenil
Jazz PharmaceuticalsPhase 2
Jardiance
Boehringer IngelheimPhase 2
Atorvastatin Calcium
Merck & Co.Phase 2
Zasocitinib
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ulcerative Colitis1 trial
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT06071312·64 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for single FMT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details